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aorta (sAAA). The natural history of these sAAAs and
whether they affect the results of EVAR are unknown.
Methods: 470 patients in theM2S database were iden-
tified as having an infrarenal abdominal aortic aneurysm
(iAAA) with a concomitant sAAA (diameter 2.9-4.7cm).
Patients with a preoperative CTA and follow-up imaging
12 months (n239) were included in the analysis. Pa-
tients who did not undergo EVAR served as a control (C)
(n81). Patients with EVARwere subdivided into suprare-
nal fixation (SR) (n94) and infrarenal fixation(IR)
(n64). Standard measurements from the M2S images
were extracted, and growth rates were calculated for differ-
ent abdominal aortic segments.
Results: The average follow-up was 32.1  19.8
months. The average initial size and growth rate of the sAAA
was 34.503.31mm and 0.561.35mm/yr for patients un-
dergoing EVAR (SRIR) compared with 36.683.67mm
(P.05) and 0.602.87mm/yr (P.17) for controls. Fol-
lowing EVAR, 1.3% of patients (SR-1/941.1%; IR
1/641.6%) experienced sAAA growth to a diameter
50mmwhichwas not significantly different from the control
group (4/814.9%, P.09) and occurred at a mean of 43.5
months (range 9.8-59.4). Comparing the SR and IR
groups, there was no difference in the preoperative sAAA
diameter (SR 34.663.09mm, IR 34.263.61, P.75).
Postoperative sAAA growth rate (SR 0.561.20mm/yr, IR
0.551.55, P.98), aortic growth rate at the renals (SR
1.001.81mm/yr, IR 0.901.50, P.69), iAAA growth
rate (SR -1.685.79mm/yr, IR -1.385.09, P.73), and
iAAA change in volume (SR -10.5834.65mL/yr, IR
-6.1129.14, P.40) were also not significantly different.
Conclusions: Isolated treatment of iAAA via EVAR
with a concomitant sAAA is acceptable as the endograft
(suprarenal or infrarenal) does not affect growth rates of the
sAAA. Standard EVAR follow-up is all that is required as
only a small minority demonstrate growth.
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Objectives: The Endurant endograft was specially de-
veloped to broaden the treatment range for EVAR in
patients with complex aortoiliac anatomy. Preliminary re-
ports showed excellent outcome concerning migration and
type IA endoleaks, but occurrence of post-EVAR obstruc-
tion has not been determined in a large patient cohort with
mid-term follow-up (FU).
Methods: Data of all consecutive patients treated with
the Endurant from December 2007 to April 2011 in 3
Dutch tertiary referral hospitals were prospectively gath-
ered. FU consisted of regular office visits, 1 and 12 months
CT-scans, and annual duplex scanning thereafter. Patients
with either a symptomatic stenosis or complete occlusion of
the Endurant endograft were identified.
Results: 428 patients (88.3% male, mean age 73 years
(range 47-89)) were treated. Median FU was 12 months
(range 0-43). 22 obstructions occurred in 21 patients
(4.9%), either of the main body of the graft (n3), a limb
(n18) or unknown (n1). Median time to obstruction
was 6 months (range 0-22), with 27.3% occurring 12
months post-EVAR. Presenting symptoms were acute isch-
emia (40.9%, Rutherford 2A-B) or non acute (59.1%). The
latter were mainly claudicants without rest pain, and diag-
nosed at regular FU. Treatment was surgical (63.6%) or
percutaneous (18.2%), the remainder was left untreated
due to mild clinical complaints. Initial treatment was suc-
cessful in 19 of 22 obstructions (86.4%), but re-obstruction
occurred in 6 (31.6%). In 40.9%of obstructions a graft related
complication (kinking, stenosis or collapse) was found. Mor-
tality due to obstruction of the endograft was 0.7% (3/428) in
all patients, and 14.3% (3/21) in the obstruction group; 2
patients died because of ongoing ischemia, and 1 patient died
intra-operatively due to bleeding.
Conclusions: Endurant endograft obstruction oc-
curred in 4.9% of 428 patients, and continued during FU.
It is an important complication that must be considered in
expanding the indications for EVAR.
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